This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gaita, F. Articles by Wolpert, C. Search for Related Content PubMed PubMed Citation Articles by Gaita, F. Articles by Wolpert, C.

Short QT syndrome: pharmacological treatment

Fiorenzo Gaita, MD^*,*, Carla Giustetto, MD^*, Francesca Bianchi, MD^*, Rainer Schimpf, MD, Michel Haissaguerre, MD, Leonardo Calò, MD, Ramon Brugada, MD^||, Charles Antzelevitch, PhD^¶, Martin Borggrefe, MD and Christian Wolpert, MD

^* Division of Cardiology, Ospedale Civile di Asti, Asti, Italy
Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
Division of Cardiology, Haut-Leveque, Bordeaux-Pessac, France
Department of Cardiac Diseases, San Filippo Neri Hospital, Rome, Italy
^|| Molecular Genetics, Masonic Medical Research Laboratory, Utica, New York, USA
^¶ Experimental Cardiology Programs, Masonic Medical Research Laboratory, Utica, New York, USA

View larger version (87K): [in a new window]   Figure 1 Twelve-lead electrocardiographic (ECG) recordings of Patient 1, while treated with different antiarrhythmic drugs. From left to right: basal ECG; during oral flecainide administration, oral sotalol, ibutilide, and hydroquinidine. During hydroquinidine administration: QT prolongation and ST-T changes: appearance of ST-segment, T-wave increases in duration.